Earnings misses, weak guidance, and downgrades drove large-cap decliners—led by Synopsys, Chewy, and The Trade Desk—while biotech trial updates and mixed analyst calls pressured others.
Earnings misses, weak guidance, and downgrades drove large-cap decliners—led by Synopsys, Chewy, and The Trade Desk—while biotech trial updates and mixed analyst calls pressured others.